Abstract

Similar articles

• Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: relationships with antibiotic use and cost drivers.

  Mauldin PD, Salgado CD, Durkalski VL, Bosso JA.Mauldin PD, et al.Ann Pharmacother. 2008 Mar;42(3):317-26. doi: 10.1345/aph.1K501. Epub 2008 Feb 19.Ann Pharmacother. 2008.PMID:18285560
• Risk of acquiring antibiotic-resistant bacteria from prior room occupants.

  Huang SS, Datta R, Platt R.Huang SS, et al.Arch Intern Med. 2006 Oct 9;166(18):1945-51. doi: 10.1001/archinte.166.18.1945.Arch Intern Med. 2006.PMID:17030826
• Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.

  Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, Dukart G, Babinchak T, Cooper CA, Ellis-Grosse EJ, Dartois N, Gandjini H; 307 Study Group.Florescu I, et al.J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i17-28. doi: 10.1093/jac/dkn250.J Antimicrob Chemother. 2008.PMID:18684703Clinical Trial.
• Antimicrobial resistance in gram-positive bacteria.

  Rice LB.Rice LB.Am J Infect Control. 2006 Jun;34(5 Suppl 1):S11-9; discussion S64-73. doi: 10.1016/j.ajic.2006.05.220.Am J Infect Control. 2006.PMID:16813977Review.
• [Hospital infection control measures for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci].

  Hori S.Hori S.Nihon Rinsho. 2002 Nov;60(11):2144-9.Nihon Rinsho. 2002.PMID:12440120Review.Japanese.

Cited by

• Aminoglycoside use in intensive care units and aminoglycoside nephrotoxicity. Comment letter 1.

  Pogue JM, Potoski BA, Kaye KS.Pogue JM, et al.Antimicrob Agents Chemother. 2010 Jun;54(6):2750, author reply 2751. doi: 10.1128/AAC.00892-09.Antimicrob Agents Chemother. 2010.PMID:20479210Free PMC article.No abstract available.
• The importance of adjusting for enterococcus species when assessing the burden of vancomycin resistance: a cohort study including over 1000 cases of enterococcal bloodstream infections.

  Kramer TS, Remschmidt C, Werner S, Behnke M, Schwab F, Werner G, Gastmeier P, Leistner R.Kramer TS, et al.Antimicrob Resist Infect Control. 2018 Nov 14;7:133. doi: 10.1186/s13756-018-0419-9. eCollection 2018.Antimicrob Resist Infect Control. 2018.PMID:30459945Free PMC article.
• Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).

  Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN.Rybak MJ, et al.J Clin Microbiol. 2008 Sep;46(9):2950-4. doi: 10.1128/JCM.00582-08. Epub 2008 Jul 16.J Clin Microbiol. 2008.PMID:18632899Free PMC article.
• Antimicrobial drug use in food-producing animals and associated human health risks: what, and how strong, is the evidence?

  Hoelzer K, Wong N, Thomas J, Talkington K, Jungman E, Coukell A.Hoelzer K, et al.BMC Vet Res. 2017 Jul 4;13(1):211. doi: 10.1186/s12917-017-1131-3.BMC Vet Res. 2017.PMID:28676125Free PMC article.Review.
• Community-associated methicillin-resistantStaphylococcus aureus infection: Literature review and clinical update.

  Loewen K, Schreiber Y, Kirlew M, Bocking N, Kelly L.Loewen K, et al.Can Fam Physician. 2017 Jul;63(7):512-520.Can Fam Physician. 2017.PMID:28701438Free PMC article.Review.

References

Publication types

• Comparative Study

MeSH terms

• Cohort Studies
• Control Groups
• Enterococcus*
• Hospitalization / economics
• Humans
• Methicillin Resistance*
• Multivariate Analysis
• Staphylococcal Infections / drug therapy*
• Staphylococcal Infections / economics
• Staphylococcus aureus*
• Vancomycin Resistance*
• Wound Infection / drug therapy*
• Wound Infection / economics

Related information

• PubChem Compound
• PubChem Substance

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central

• Medical

  • MedlinePlus Health Information